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INTRODUCTION
terized first by a severe peripheral neuropathy (typically resulting in limb amputation) and deafness, followed by dementia and variably cerebellar ataxia. 5 Herein, we describe a patient with sporadic late age of onset of narcolepsy, cerebellar ataxia, and hearing loss, with a novel de novo mutation in exon 21.
CASE DESCRIPTION
A 31-year-old woman of Italian descent presented with ataxia, deafness, and narcolepsy. She had a 10-year history of narcolepsy treated with methylphenidate 20 mg daily. She denied cataplexy, hallucinations, or sleep paralysis. Polysomnographic and multiple sleep latency testing were consistent with narcolepsy (mean sleep latency 1.3 minutes and 5 sleep onset REM periods in 5 naps). HLA-DQB1*06:02 was positive. At age 24, she started to have tinnitus and progressive hearing loss, diagnosed by audiogram as of sensory origin. Gait instability occurred progressively over the last 6 years. She also had primary amenorrhea. The patient denied memory loss or psychiatric symptoms. Transthoracic echocardiogram was normal. FSH, estradiol, LH, testosterone, and thyroid axis values were within normal range. Neurological examination showed moderate axial and appendicular ataxia, mild vertical nystagmus, and absent lower limb tendon reflexes, but no sensory deficits, ulcerations, lymphedema, or optic atrophy. Mild brain atrophy was observed on MRI, with cerebellar involvement. CSF hypocretin-1 was 191 pg/mL (normal values > 200 pg/mL), indicating low to intermediary decreased levels, as found in other cases at this stage of the disease. DNMT1 exon 20 and exon 21 were sequenced. A non-synonymous mutation p.Cys596Arg (NM_001130823.1: c.1786T > C) was found in exon 21, substituting a conserved cysteine residue by arginine. This mutation was not found in 90 controls sequenced previously and in the 1000 genomes. The mother and 3 siblings were tested and had wild-type alleles ( Figure 1 ). Haplotyping of 14 markers surrounding the mutation indicated de novo status for c.1786T > C in the proband ( Figure 1 and Table S1 ). The father died at age 69 from laryngeal cancer and had no neurological symptoms.
DISCUSSION
The novel de novo DNMT1 mutation described here is remarkable as it further demonstrates that another exon 21 mutation of the DNMT1 RFTS domain causes cerebellar ataxia, deafness, and narcolepsy. Consistent with the likely disruptive effect of this polar substitution, onset was similar to that of patients with p.Val606Phe and earlier than in patients with p.Ala570Val and p.Gly605Ala mutations.
3 In all ADCA-DN patients with exon 21 mutations 3 and unlike in HSN1E patients with exon 20 mutations, 5 peripheral neuropathy is a late symptom, whereas narcolepsy and cerebellar ataxia are consistent symptoms. Deafness is also present as an early symptom, while dementia occurs later in the disease, with optic atrophy and other symptoms. It remains to be seen if narcolepsy is also a variable or later onset feature of exon 20 HSN1E mutations, as in 3 cases in a multiplex pedigree, occasional somnolence in the fifth decade was noted.
6
How these mutations could induce late onset neurodegeneration is unknown. Both hyper-and hypomethylation have been shown to induce neuronal cell death in various models. 7, 8 The DNMT1 RFTS domain is inhibitory, thus impairment would likely produce hypermethylation, a gain of function consistent with the dominant effect of these mutations. In its biochemical studies of exon 20 mutations, Klein et al. 5 mostly found decreased enzyme activity, and decreased genome wide methylation using the bisulfide technique. A suggestion of impaired nuclear localization of the mutant protein was also found indicating decreased activity. 5 Interestingly, however, selected CpG island loci displayed significantly increased methylation, loci that could be more important functionally. Clarifying whether these mutations lead to increased or decreased function, or off-target methylation (hemi-methylated versus un-methylated DNA for example), together with the identification of target genes relevant to the phenotype will likely be essential to the design of future therapies for these patients.
Since the discovery of the cause of this syndrome in 4 families with three mutations in exon 21, one more multigenerational family with the syndrome was also discovered in the UK (John Ealing, Personal communication) and found to have p.Ala570Val, a mutation already reported in two other pedigrees. 3 Together with the report described here, a total of six families with 4 distinct mutations (2 de novo mutations, 4 autosomal dominant pedigrees) in exon 21 have been found to cause ADCA-DN, with onset of the full syndrome at age 30-50. All cases progress to dementia not otherwise specified, but without Lewy body or amyloid plaques at autopsy. We believe that many more such families will be identified in the future.
The most striking feature of the syndrome may be the earlier onset of narcolepsy without cataplexy (sleepiness with rapid transitions into REM sleep during the MSLT) up to 20 years before the onset of the other symptoms. At this early stage, the diagnosis is unlikely to be made, as this is a common diagnosis without major health consequences. At a later stage, narcolepsy may manifest unusually with cataplexy in a middle age subject with deafness and/or ataxia, often without DQB1*06:02 (a marker of sporadic autoimmune narcolepsy-cataplexy), and with intermediary CSF hypocretin-1 levels.
3,9 Associated psychiatric presentations such as psychosis or depression are ) derived using surrounding the mutation. Haplotypes were derived using rs8112063, rs7710, rs3826784, rs2290684, and rs7253062 (see Table S1 ). Note that all 4 parental haplotypes could be characterized in asymptomatic siblings without the mutation, indicating that the mutation is de novo in the patient. (B) Exon 21 of DNMT1 gene with arrows indicating the four mutations so far found in ADCA-DN patients and an overview of the degree of conservation of the region containing the four known mutations. p.Cys596Arg is the new mutation described in our patient.
possible. MRI may show minor cerebellar and supratentorial atrophy, pronounced dilatation of the third ventricle, low T2-signal intensity in the basal ganglia, and loss of cerebral cortexwhite matter differentiation. 2 Neurological examination can be borderline abnormal, suggesting cerebellar ataxia, mild peripheral neuropathy, or other abnormalities. Assessment of visual acuity, pupils, peripheral vision, color vision, electroretinography, visual evoked potential, and optical coherence tomography may also reveal early signs consistent with progressing optic nerve atrophy. Early recognition of this syndrome will likely be important in the future, as therapy, if efficacious, will be needed early to delay onset of the fatal symptoms.
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